预防性ICD植入的当前标准:EU-CERT-ICD(评估欧洲主要ProphylacTic植入式心律转复除颤器使用的比较有效性研究)项目的见解
Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project
摘要:
背景一级预防植入式心律转复除颤器(ICD)治疗的临床有效性仍存在争议。迫切需要更好地识别从预防性ICD治疗中获益的患者。2019年完成的评估原发性预防性植入式心律转复除颤器(EU-CERT-ICD)使用的EUROCERT比较有效性研究将评估这一问题。摘要EU-CERT-ICD是一项在15个欧洲国家的44个中心进行的前瞻性研究者发起的非随机、对照、多中心观察性队列研究。在2014年至2018年期间,共招募了2327例因缺血性心脏病或扩张型心肌病导致的心力衰竭患者,适用于一级预防性ICD植入术(首次植入ICD时>1500例患者,非随机非ICD对照组>750例患者)。主要终点为全因死亡率,首次适当电击为协同主要终点。基线时,所有患者均接受12导联ECG和Holter-ECG分析,使用多种先进方法进行风险分层以及记录临床特征和实验室值。EU-CERT-ICD数据将提供关于预防性ICD治疗的生存获益的急需信息,并扩展既往前瞻性风险分层研究,这些研究显示临床参数和高级风险分层指标具有非常好的适用性,以定义ICD获益高于或低于平均水平的患者亚组。结论EU-CERT-ICD研究将提供关于初次预防性ICD植入有效性的新数据和最新数据。该研究还旨在改善风险分层和患者选择,一般使用临床风险标志物,特别是高级ECG风险标志物。
英文摘要:
BACKGROUND. The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. It is urgently needed to better identify patients who benefit from prophylactic ICD therapy. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) completed in 2019 will assess this issue. SUMMARY. The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicenter observational cohort study done in 44 centers across 15 European countries. A total of 2327 patients with heart failure due to ischemic heart disease or dilated cardiomyopathy indicated for primary prophylactic ICD implantation were recruited between 2014 and 2018 (>1500 patients at first ICD implantation, >750 patients non-randomized non-ICD control group). The primary endpoint was all-cause mortality, first appropriate shock was co-primary endpoint. At baseline, all patients underwent 12-lead ECG and Holter-ECG analysis using multiple advanced methods for risk stratification as well as documentation of clinical characteristics and laboratory values. The EU-CERT-ICD data will provide much needed information on the survival benefit of preventive ICD therapy and expand on previous prospective risk stratification studies which showed very good applicability of clinical parameters and advanced risk stratifiers in order to define patient subgroups with above or below average ICD benefit. CONCLUSION. The EU-CERT-ICD study will provide new and current data about effectiveness of primary prophylactic ICD implantation. The study also aims for improved risk stratification and patient selection using clinical risk markers in general, and advanced ECG risk markers in particular.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。